Holen Sie sich die Stockscreener-App
2.09
1.65%
-0.035
Handel nachbörslich:
2.09
Schlusskurs vom Vortag:
$2.125
Offen:
$2.06
24-Stunden-Volumen:
11,124
Relative Volume:
0.68
Marktkapitalisierung:
$32.38M
Einnahmen:
$22.06M
Nettoeinkommen (Verlust:
$-30.94M
KGV:
-0.933
EPS:
-2.24
Netto-Cashflow:
$-26.70M
1W Leistung:
-2.67%
1M Leistung:
-8.33%
6M Leistung:
-62.21%
1J Leistung:
-36.86%
1-Tages-Spanne:
$2.04
$2.2225
1-Wochen-Bereich:
$1.90
$2.42
52-Wochen-Spanne:
$1.90
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Firmenname
Casi Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CASI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
2.09 | 32.38M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Eingeleitet | Mizuho | Buy |
| 2020-10-23 | Eingeleitet | Oppenheimer | Outperform |
| 2016-09-22 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Casi Pharmaceuticals Inc Aktie (CASI) Neueste Nachrichten
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
CASI Pharma stock hits 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks
Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics - MarketScreener
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharmaceuticals receives buyout proposal from CEO - Investing.com India
CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations - TipRanks
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - ACCESS Newswire
CASI Pharma's CEO Makes Strategic $20M Bid for Entire China BusinessKey Pipeline Assets Included - Stock Titan
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Yahoo Finance
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 15.0% - Defense World
CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments - TipRanks
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - ACCESS Newswire
CASI Delivers Record Q4 Growth: FDA Clearance Powers Next-Gen Treatment Pipeline - Stock Titan
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com - Defense World
CASI Pharma stock hits 52-week low at $2.04 amid market challenges - Investing.com
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute - TipRanks
Assenagon Asset Management S.A. Increases Stock Holdings in Premier, Inc. (NASDAQ:PINC) - Defense World
Can this 10.8% yield from a FTSE 250 share last? - Yahoo Finance UK
CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals Launches Pivotal Phase 1/2 Trial for Novel ITP Treatment CID-103 - StockTitan
Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld Online
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
Is a stock market crash coming? And what should I do now? - Yahoo Finance UK
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
Pre-market Movers: SXTC, STIM, BIOA, UPC... - RTTNews
Switch Therapeutics Appoints David M. Holtzman, M.D., to Its Scientific Advisory Board and Announces Its First Development Candidate, CASi-APOE, a Liver-Sparing APOE RNAi Therapy - BioSpace
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
Finanzdaten der Casi Pharmaceuticals Inc-Aktie (CASI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):